Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 93Active not recruiting 57Completed 14Not yet recruiting 8Terminated 5Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Radiation 4fludarabine 2daratumumab 2Temozolomide 2Specimen Handling 2Radiotherapy 2Irinotecan 2Gemcitabine 2Cytarabine 2Biopsy 2ALT-803 2vocimagene amiretrorepvec 1revumenib 1pembrolizumab 1pelcitoclax 1olutasidenib 1merphos 1irinotecan sucrosofate 1dexamethasone acetate 1dexamethasone 21-phosphate 1dehydroftorafur 1decitabine and cedazuridine drug combination 1carfilzomib 1balstilimab 1auricularum 1X-Rays 1Vorinostat 1Transurethral Resection of Prostate 1Taxes 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Cisplatin × 30 days × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡